Reply

[...]it is important to note that the patients in our study were not treatment-naïve patients; all were previously treated with either bevacizumab or ranibizumab.1 In the VIEW 1-2 studies,2 every-other-month aflibercept treatment reduced treatment burden while maintaining noninferiority to monthly r...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of ophthalmology Vol. 170; p. 247
Main Authors Muftuoglu, Ilkay Kilic, Arcinue, Cheryl A, Alam, Mostafa, Gaber, Raouf, Camacho, Natalia, You, Qisheng, Tsai, Frank F, Freeman, William R
Format Journal Article
LanguageEnglish
Published Chicago Elsevier Limited 01.10.2016
Online AccessGet full text

Cover

More Information
Summary:[...]it is important to note that the patients in our study were not treatment-naïve patients; all were previously treated with either bevacizumab or ranibizumab.1 In the VIEW 1-2 studies,2 every-other-month aflibercept treatment reduced treatment burden while maintaining noninferiority to monthly ranibizumab in treatment-naïve patients. [...]it would be inappropriate to make direct comparisons of the treatment regimens between the 2 studies.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2016.08.001